Scientists at Keio University Hospital have successfully transplanted iPS cell-derived neural stem/progenitor cells (iPSC-NS/PCs) into a patient, to start the first-in-human clinical study for the treatment of spinal cord injury using iPSC-derived cells.
MiRNA as a Novel Therapy for Myocardial FibrosisMarch 21, 2022
US Research reveals the role of Heparan Sulfate in ObesityMarch 1, 2022
Ps: Image in fig 1 is reproduced from Sato, T. et al. (2021). Neuroscience Letters, 746, 135676. Generation of region-specific and high-purity neurons from human feeder-free iPSCs. under a Creative Commons license (CC BY 4.0).
The surgery is the first transplant of human iPS cell-derived neuronal progenitor cells for spinal cord injury. Based on the data up to about 3 months after transplantation to the first patient, an independent Monitoring Committee of experts will assess the treatment’s safety. The team will proceed with the second transplant, if the committee confirms it is safe to continue the project. As a result, they are currently suspending the recruitment of the following participants, and the resumption of recruitment will be expected to be around March.
At a press conference, Hideyuki Okano, the research group leader, said “I am glad to come to this stage after overcoming various difficulties.”